Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells

Cancer Research

Volumn 65, Issue 15, 2005, Pages 6640-6650

  Huss, Wendy J ^a   Gray, Danny R ^a   Greenberg, Norman M ^c,d   Mohler, James L ^a,b,e,f   Smith, Gary J ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

^f UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; BREAST CANCER RESISTANCE PROTEIN; CELL MARKER; FUMITREMORGIN C; MESSENGER RNA; MYCOTOXIN; NOVOBIOCIN; NUCLEAR FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL CELL; CANCER HORMONE THERAPY; CASTRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG SENSITIVITY; GENE EXPRESSION; HORMONE TRANSPORT; HUMAN; HUMAN TISSUE; HYPOXIA; MALE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN STABILITY; RAT; RECURRENT CANCER; SIMIAN VIRUS 40; STEM CELL; TRANSGENIC MOUSE; TREATMENT FAILURE; TUMOR DIFFERENTIATION; TUMOR XENOGRAFT;

ANDROGENS; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; CELL NUCLEUS; HUMANS; INDOLES; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM PROTEINS; NOVOBIOCIN; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RECEPTORS, ANDROGEN; RNA, MESSENGER; TRANSPLANTATION, HETEROLOGOUS; TUMOR STEM CELLS;

EID: 23044510643     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2548     Document Type: Article

References (52)

1. Pierce GB. Neoplasms, differentiations and mutations. Am J Pathol 1974;77:103-18.
2. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
3. Isaacs JT, Coffey DS. Etiology and diseuse process of benign prostatic hyperplasia. Prostate Suppl 1989;2:33-50.
4. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996;28: 98-106.
5. Schalken JA, van Leenders G. Cellular and molecular biology of the prostate: stem cell biology. Urology 2003; 62:11-20.
6. Slack JM. Stem cells in epithelial tissues. Science 2000;287:1431-3.
7. Bunting KD. ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells 2002;20:11-20.
8. Doyle LA, Boss DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22:7340-58.
9. Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y. Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol 2003;64:610-8.
10. Cunfaa GR, Cooke PS, Kurita T. Role of stromal-epithelial interactions in hormonal responses. Arch Histol Cytol 2004;67:417-34.
11. Kurita T, Medina RT, Mills AA, Cimha GR. Role of p63 and basal cells in the prostate. Development 2004;131: 4935-64.
12. Presnell SC, Werdin ES, Maygarden S, Mohler JL, Smith GJ. Establishment of short-term primary human prostate xenografts for the study of prostate biology and cancer. Am J Pathol 2001;159:855-60.
13. Huss WJ, Gray DR, Werdin ES, Funkhouser WK Jr, Smith GJ. Evidence of pluripoteut human prostate stem cells in a human prostate primary xenograft model. Prostate 2004;60:77-90.
14. Kaplan-Lefko PJ, Chen TM, Ittmann MM, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55: 219-37.
15. Presnell SC, Glover WJ, Borchert KM, Gregory CW, Mohler JL, Smith GJ. Isolation and partial characterization of an epithelial cell line (RPE-F344) from the regenerating prostate of a normal adult male rat. Prostate Cancer Prostatic Dis 1999;2:257-63.
16. Jonker JW, Buitelaar M, Wagenaar E, et al. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A 2002;99:15649-54.
17. Woodham C, Birch L, Prins GS. Neonatal estrogen down-regulates prostatic androgen receptor through a proteosome-mediated protein degradation pathway. Endocrinology 2003;144:4841-50.
18. O'Neill RR, Mitchell LG, Merril CR, Rasband WS. Use of image analysis to quantitate changes in form of mitochondrial DNA after X-irradiation. Appl Theor Electrophor 1989;1:163-7.
19. Johnson MA, Iversen P, Schwier P, et al, Castration triggers growth of previously static androgen-independent lesions in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Prostate 2005;62:322-38.
20. Mirosevich J, Gao N, Gupta A, Shappell SB, Matusik RJ. The expression and role of Foxa proteins in prostate cancer. The Prostate. In press 2005,
21. Shiozawa K, Oka M, Soda H, et al, Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int J Cancer 2004;108:146-51.
22. Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH, Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res 2003;63:1339-44.
23. Chen ZS, Robey RW, Belinsky MG, et al. Transport of methotrexate, methotrexate polyglutamates, and 17β-estradiol 17-(β-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res 2003;63:4048-54.
24. Lockhart AC, Tirona RG, Kim RB. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther 2003;2:685-98.
25. Guo Y. Lubbert M, Engelhardt M, CD34- hematopoietic stem cells: current concepts and controversies. Stem Cells 2003;21:15-20.
26. Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001;7:1028-34.
27. Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD, Sorrentino BP, Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci U S A 2002;99:12339-44.
28. Scheffer GL, Pijnenborg AC, Smit EF, et al, Multidrug resistance related molecules in human and murine lung. J Clin Pathol 2002;55:332-9.
29. Summer R, Kotton DN, Sun X, Ma B, Fitzsimmons K, Fine A. Side population cells and Bcrpl expression in lung. Am J Physiol Lung Cell Mol Physiol 2003;285: L97-104.
30. van Weerden WM, Romijn JC. Use of nude mouse xenograft models in prostate cancer research. Prostate 2000;43:263-71.
31. Heinlein CA, Chang C. Androgen receptor in prostate cancer, Endocr Rev 2004;25:276-308.
32. Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 2004;14:43-7.
33. Rennie PS, Bruchovsky N, Leco KJ, et al, Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol 1993;7:23-36.
34. Monaghan AP, Kaestner KH, Grau E, Schutz G. Postimplantation expression patterns indicate a role for the mouse forkhead/HNF-3 α, β and γ genes in determination of the definitive endoderm, chordamesoderm and neuroectoderm. Development 1993;119: 567-78.
35. Mirosevich J, Gao N, Matusik RJ. Expression of Foxa transcription factors in the developing and adult murine prostate. Prostate 2005;62;339-52.
36. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 1999;59: 2203-9.
37. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 2001;61:2736-43.
38. Huss WJ, Barrios RJ, Foster BA, Greenberg NM. Differential expression of specific FGF iigand and receptor isoforms during angiogenesis associated with prostate cancer progression. Prostate 2003;54:8-16.
39. Uzgare AR, Kaplan PJ, Greenberg NM. Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate 2003;55:128-39.
40. Maddison LA, Huss WJ, Barrios RM, Greenberg NM. Differential expression of cell cycle regulatory molecules and evidence for a "cyclin switch" during progression of prostate cancer. Prostate 2004;58:335-44.
41. Wikstrom P, Lindahl C, Bergh A. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy. Prostate 2005;62:148-64.
42. Kurita T, Wang YZ, Donjacour AA, et al. Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ 2001;8:192-200.
43. Lekas E, Johansson M, Widmark A, Bergh A, Damber JE. Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration. Urol Res 1997;25:309-14.
44. Buttyan R, Shabsigh A, Perlman H, Colombel M. Regulation of apoptosis in the prostate gland by androgenic steroids. Trends Endocrinol Metab 1999;10: 47-54.
45. Shabsigh A, Chang DT, Heitjan DF, et al. Rapid reduction in blood flow to the rat ventral prostate gland after castration: preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. Prostate 1998;36:201-6.
46. Shabisgh A, Tanji N, D'Agati V et al. Early effects of castration on the vascular system of the rat ventral prostate gland. Endocrinology 1999;140:1920-6.
47. Shabsigh A, Ghafar MA, de la Taille A, et al. Biomarker analysis demonstrates a hypoxic environment in the castrated rat ventral prostate gland. J Cell Biochem 2001;81:437-44.
48. Krishnamurthy P, Hoss DD, Nakanishi T, et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 2004;279:24218-25.
49. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1α and insulin-like growth factor 2. Cancer Res 1999;59:3915-8.
50. Mohler JL, Gregory CW, Ford OH III, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10;440-8.
51. Imai Y, Nakane M, Kage K, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002;1: 611-6.
52. Zamber CP, Lamba JK, Yasuda K, et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 2003;13:19-28.